Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Atu027

Oligonucleotide (siRNA) · Gene silencing: protein kinase N3 (PKN3) mRNA (PKN3) · developed by Silence Therapeutics GmbH

Phase 1/2 Most advanced trial (none active)
SLN Developer
2 Registered trials

What is Atu027?

Atu027 is a lipoplexed formulation of short-interfering RNAs directed against PKN3, encapsulated in cationic and fusogenic lipids that promote uptake by tumor cells. The siRNAs bind PKN3 mRNA to inhibit its translation. It is studied in advanced solid tumors and pancreatic ductal carcinoma.

Summary written with AI from the sources listed at the end of this page.

At a glance

Drug type
Oligonucleotide (siRNA)
Targets
protein kinase N3 (PKN3) mRNA (PKN3)
Mechanism
Gene silencing: protein kinase N3 (PKN3) mRNA (PKN3)
Pathways
PI3K signaling, invasive cell growth and metastasis
Therapy area
Oncology
Developer
Silence Therapeutics GmbH (SLN)
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 1/2
UNII
IFJ2SAK127

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT01808638 Phase 1/2 Carcinoma, Pancreatic Ductal Completed SLN
NCT00938574 Phase 1 Advanced Solid Tumors Completed SLN

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Advanced Solid TumorsCarcinoma, Pancreatic Ductal

More from Silence Therapeutics GmbH

Sources

Updated Nov 1, 2026. Something wrong or missing? Report it on the SLN page.

Follow SLN, the company behind Atu027

See SLN's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

SLN catalysts and pipeline →
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.